Drug intelligence / Profile preview

IN-2502

Development stage: Preclinical
Lead developer: Indivumed

Overview

IN-2502 is a preclinical biologic drug candidate being developed by Indivumed for the treatment of colorectal cancer (CRC). The drug was identified through Indivumed's proprietary multi-omics platform, which analyzes high-quality patient biospecimens to discover novel therapeutic targets. As of September 2025, IN-2502 is in the 'Hit to Lead' stage of development. While the specific molecular target and mechanism of action have not been publicly disclosed by the company, the program is part of a specialized pipeline aimed at addressing the molecular drivers of CRC and potentially other solid tumors.

Beyond the preview

Go deeper on IN-2502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-2502.

Explore the full profile